NDC 0002-3977

RETEVMO

Selpercatinib

RETEVMO is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Selpercatinib.

Product ID0002-3977_1ebfa429-955a-4e8b-a1bf-b77f5e790780
NDC0002-3977
Product TypeHuman Prescription Drug
Proprietary NameRETEVMO
Generic NameSelpercatinib
Dosage FormCapsule
Route of AdministrationORAL
Marketing Start Date2020-05-08
Marketing CategoryNDA / NDA
Application NumberNDA213246
Labeler NameEli Lilly and Company
Substance NameSELPERCATINIB
Active Ingredient Strength40 mg/1
Pharm ClassesBreast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 0002-3977-60

60 CAPSULE in 1 BOTTLE (0002-3977-60)
Marketing Start Date2020-05-08
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0002-3977-60 [00002397760]

RETEVMO CAPSULE
Marketing CategoryNDA
Application NumberNDA213246
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2020-05-08

Drug Details

NDC Crossover Matching brand name "RETEVMO" or generic name "Selpercatinib"

NDCBrand NameGeneric Name
0002-2980RETEVMOselpercatinib
0002-3977RETEVMOselpercatinib

Trademark Results [RETEVMO]

Mark Image

Registration | Serial
Company
Trademark
Application Date
RETEVMO
RETEVMO
88332283 not registered Live/Pending
Eli Lilly and Company
2019-03-08

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.